As a former chair of an NIH section, it is not clear to me that a “strong chair” model is what CSR wants. I wanted to implement several changes and there was concern that the chair would have undue influence. They really see the chair as a traffic cop. I don’t agree, but it was my experience.
We use an anti E.coli RpoB antibody from Biolegend that reacts with mycobacterial RpoB. Can’t speak to cross reactivity with other species.
Paper 1 led by Samar Atteih: We observe dampening of inflammatory signals and restriction of microbial nutrients in the upper respiratory tract of CF patients treated with triple modulators: onlinelibrary.wiley.com/doi/10.1002/...onlinelibrary.wiley.com/share/author...
Paper 2 led by Anna Zemke (still at Pitt and a super collaborator) finds that triple modulator therapy favorably changes the sinus microbiome: 🧪🧫🧬. thanks for checking this out! onlinelibrary.wiley.com/doi/10.1002/...
Valerie Mizrahi is one of them! #WomenInStemwww.nature.com/articles/s41...
Tuberculosis is the leading cause of death from a single infectious agent, with over 25% of these occurring in the African region. Multi-drug resistant strains which do not respond to first-line antib...
My favorite part: “And in biomedical science, there is an increasing tendency to equate significance to any form of medical relevance. This causes biochemical investigations and research on nonmammalian systems to be treated as intrinsically less valuable than studies on human cells. “ 🦠
Thanks for suggesting bluesky and for your generous introduction!